FAQ: Calidi Biotherapeutics $6 Million Public Offering and Company Overview

What is the main announcement from Calidi Biotherapeutics?

Calidi Biotherapeutics announced the pricing of an underwritten public offering for gross proceeds of $6 million before expenses to support its clinical-stage biotechnology development.

What specific securities are being offered in this public offering?

The offering includes approximately 1.47 million common stock units priced at $2.00 each and approximately 1.53 million pre-funded warrant units priced at $1.999 each, both paired with Series I warrants exercisable at $2.00 per share for five years.

Who is managing this public offering?

Ladenburg Thalmann is serving as sole book-running manager with Laidlaw & Company (U.K.) Ltd. as co-manager for the offering.

What type of company is Calidi Biotherapeutics and what do they develop?

Calidi Biotherapeutics is a clinical-stage immuno-oncology company pioneering targeted therapies that deliver genetic medicines to distal disease sites using their proprietary Redtail platform featuring engineered enveloped oncolytic viruses.

How does Calidi’s Redtail platform technology work?

The Redtail platform uses engineered enveloped oncolytic viruses designed for systemic delivery that shield the virus from immune clearance, allowing virotherapy to reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.

What cancer types is Calidi’s lead candidate targeting?

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need.

Where can investors find more information about Calidi Biotherapeutics?

The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI.

What is TinyGems and how are they involved with this content?

TinyGems is a specialized communications platform focused on innovative small-cap and mid-cap companies, and is part of the Dynamic Brand Portfolio at IBN that provides distribution services for company news and updates.

What is the significance of this $6 million public offering for Calidi?

This $6 million public offering provides crucial funding to advance Calidi’s clinical-stage development of targeted cancer therapies and support their ongoing IND-enabling studies for treating various cancer types with high unmet medical needs.